Travere Therapeutics, Inc.
NASDAQ:TVTX · NASDAQ Global Market
+$0.65 today
Vol 6.59M · Avg 2.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-22.2%
avg -137.0%
ROIC
-13.9%
avg -30.4%
ROA
-4.2%
avg -18.3%
Analysis
ROA is currently the strongest return metric at -4.2% versus its period average of -18.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Eric Dube | President, Chief Executive Officer & Director | $1.83M | — | 53 | $432,886.00 | 0.47% |
Jula Inrig | Chief Medical Officer | $1.01M | — | 51 | $113,238.00 | 0.12% |
Peter Heerma | Chief Commercial Officer | $940,394.00 | — | 55 | $140,684.00 | 0.15% |
William E. Rote | Chief Research Officer | $935,108.00 | — | 63 | $115,474.00 | 0.12% |
Christopher Cline | Chief Financial Officer | $929,557.00 | — | 41 | $118,658.00 | 0.13% |
Elizabeth E. Reed | Chief Legal Officer, General Counsel & Secretary | $713,634.00 | — | 55 | $105,211.00 | 0.11% |
Casey Logan | Chief Business Officer | — | — | — | — | — |
Angela Giannantonio | Chief People Officer | — | — | — | — | — |
Nivi Nehra | Vice President of Corporate Communications & Investor Relations | — | — | — | — | — |
Sandra Calvin | SVP, Corporate Controller & Chief Accounting Officer | — | — | 60 | $34,000.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
70
$32.69M
Net Sentiment
$32.69M
Net selling
Most Active
REED ELIZABETH E
15 transactions
1–10 of 70
Analysis
Insiders reported 0 buys worth $0.00 and 70 sells worth $32.69M over the last 12 months. That adds up to net selling of $32.69M. REED ELIZABETH E was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +3.8% (15yr)1 analysts |
| Revenue | N/A | N/A | N/A | +21.1% (15yr)4 analysts |
| Net Income | N/A | N/A | N/A | +10.1% (15yr)4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +21.1% (15yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.16B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.47B
Legend Biotech Corporation
NASDAQ:LEGN
$5.44B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.21B
Celcuity Inc.
NASDAQ:CELC
$4.16B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.73B
Disc Medicine, Inc.
NASDAQ:IRON
$2.72B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.70B
Ascentage Pharma Group International
NASDAQ:AAPG
$398.35M
Who manages TVTX?
Travere Therapeutics, Inc. (TVTX) lists 10 active executives. The top listed executive is Eric Dube, President, Chief Executive Officer & Director.
Are TVTX insiders buying or selling?
Recent insider activity shows net selling of $5.76M.
Explore More
Continue the stock analysis
Jump to another research area for this company.